Effects of Silybum Marianum on Treatment of Patients With Chronic Hepatitis C

Isfahan University of Medical Sciences

Status and phase: Completed; Phase 2

Conditions: Hepatitis C

Treatments: Drug: Silymarin

Study type: Interventional

Funder types: Other

Identifiers

NCT01292161

ASD-1213-15

Details and patient eligibility

About

The purpose of this study is to determine the effects of silymarin on outcomes of patients with hepatitis C.

Full description

Silymarin has been claimed to have a beneficial effect in various types of liver injury, including alcoholic liver disease, drug and toxin induced hepatotoxicity, and acute and chronic viral hepatitis.

Enrollment: 55 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

confirmed chronic hepatitis C (HCV Ab (+), HCV RNA (with PCR) (+)) normal or increased liver enzymes (ALT and AST) not using interferon or ribavirin due to patient sensitivity or not consenting.

Exclusion criteria

The pregnant patients patients with side effect which confirmed with rechallenge test

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

55 participants in 1 patient group

Silymarin

Other group

Description:

Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.

Treatment:

Drug: Silymarin